Patent · US Active

Oxazolopyrimidines as Edg-1 receptor agonists

US8735387B2 · kind B2 · utility

1Cited by

0References

2Claims

0Family size

Assignee

Sanofi · FR

Inventors

Dieter Kadereit · Kelkheim, DE
Matthias Schaefer · Frankfurt am Main, DE
Werngard Czechtizky · Frankfurt, DE

Key dates

Filing date	Jul 2, 2009
Grant date	May 27, 2014
Priority date	—
Expiry date	Oct 18, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R1, R2 and R3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.